MedTrace Logo

Lipids Profile in Primary Hyperparathyroidism

NCT00961701 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-09-08

No results posted yet for this study

Summary

Severe Primary hyperparathyroidism (PHP) has been associated with increased cardiovascular morbidity and mortality. Hypertension, dyslipidemia and impaired glucose tolerance were demonstrated in severe PHP, with improvement after surgery in these variables. Recent evidence suggests that the 'quality' rather than only the 'quantity' of low-density lipoprotein (LDL)-cholesterol exerts a direct influence on the cardiovascular risk. Thus, the proposed study protocol is intended to evaluate lipoprotein phenotype and LDL size and subclasses in patients with primary hyperparathyroidism.

Conditions

  • Primary Hyperparathyroidism

Sponsors & Collaborators

  • University of Palermo

    collaborator OTHER

  • University of Zurich

    collaborator OTHER

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Rafael Luboshitzky, MD · Endocrine Institute, Haemek Medical Center, Afula, Israel

  • Manfredi Rizzo, MD · University of Palermo

  • Giatgen Spinas, MD · University of Zurich

  • Kaspar Berneis, MD · University of Zurich

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-10-31
Completion
2016-10-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961701 on ClinicalTrials.gov